Abstract
Fig S7. A. Waterfall plot of ratio of well-presented MHC-II to MHC-I neoantigens across discovery patients. B. Response rates by reliance groupings across discovery patients. Chi squared tests were performed between groups. C. MHC-I presentation pathway damage as a proportion of total number of mutations split by MHC Reliance grouping. T-tests were used to compare groups. D. Proportion of patients with any damage to MHC-I antigen presentation pathway split by MHC Reliance grouping. Chi squared tests were performed between groups. E. Immunoediting in MHC-II Reliant patients measured by SOPRANO immune dN/dS. T test was used to compare means between patients with and without MHC-I pathway damage. F. TFH cell infiltration estimates stratified by MHC-reliance grouping and ICB response. Mann-Whitney U tests were used to compare means between groups.